Stocks
Charles River Laboratories International Financial Statements () |
||||||||||
| Charles River Laboratories Internationalsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 11.02.2020 | 17.02.2021 | 16.02.2022 | 22.02.2023 | 14.02.2024 | 06.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 2 621 | 2 924 | 3 540 | 3 976 | 4 129 | 4 061 | |||
| Operating Income, bln rub | 351.2 | 432.7 | 589.9 | 651.0 | 617.3 | 562.9 | ||||
| EBITDA, bln rub | ? | 581.7 | 759.1 | 854.3 | 1 036 | 1 032 | 990.4 | |||
| Net profit, bln rub | ? | 252.0 | 364.3 | 391.0 | 486.2 | 474.6 | 413.1 | |||
| OCF, bln rub | ? | 480.9 | 546.6 | 760.8 | 619.6 | 683.9 | 796.2 | |||
| CAPEX, bln rub | ? | 140.5 | 166.6 | 228.8 | 324.7 | 318.5 | 235.7 | |||
| FCF, bln rub | ? | 340.4 | 380.0 | 532.0 | 294.9 | 365.4 | 560.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| OPEX, bln rub | 607.2 | 640.8 | 744.8 | 811.7 | 885.3 | 773.4 | ||||
| Cost of production, bln rub | 1 663 | 1 850 | 2 206 | 2 513 | 2 627 | 2 692 | ||||
| R&D, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Interest expenses, bln rub | 60.9 | 86.4 | 73.9 | 59.3 | 136.7 | 131.6 | ||||
| Assets, bln rub | 4 693 | 5 491 | 7 024 | 7 603 | 8 195 | 8 004 | ||||
| Net Assets, bln rub | ? | 1 635 | 2 115 | 2 535 | 2 976 | 3 597 | 3 782 | |||
| Debt, bln rub | 2 004 | 2 135 | 2 919 | 3 097 | 3 066 | 2 759 | ||||
| Cash, bln rub | 238.0 | 228.4 | 241.2 | 233.9 | 276.8 | 210.2 | ||||
| Net debt, bln rub | 1 766 | 1 907 | 2 678 | 2 863 | 2 790 | 2 549 | ||||
| Ordinary share price, rub | 151.9 | 251.7 | 369.2 | 217.9 | 236.4 | 198.3 | ||||
| Number of ordinary shares, mln | 48.7 | 49.6 | 50.3 | 50.8 | 51.2 | 51.4 | ||||
| Market cap, bln rub | 7 404 | 12 472 | 18 568 | 11 072 | 12 110 | 10 192 | ||||
| EV, bln rub | ? | 9 170 | 14 379 | 21 246 | 13 935 | 14 900 | 12 741 | |||
| Book value, bln rub | -595 | -482 | -1 238 | -829 | -362 | -121 | ||||
| EPS, rub | ? | 5.17 | 7.35 | 7.77 | 9.57 | 9.27 | 8.04 | |||
| FCF/share, rub | 6.99 | 7.67 | 10.6 | 5.80 | 7.13 | 10.9 | ||||
| BV/share, rub | -12.2 | -9.73 | -24.6 | -16.3 | -7.07 | -2.35 | ||||
| EBITDA margin, % | ? | 22.2% | 26.0% | 24.1% | 26.1% | 25.0% | 24.4% | |||
| Net margin, % | ? | 9.61% | 12.5% | 11.0% | 12.2% | 11.5% | 10.2% | |||
| FCF yield, % | ? | 4.60% | 3.05% | 2.87% | 2.66% | 3.02% | 5.50% | |||
| ROE, % | ? | 15.4% | 17.2% | 15.4% | 16.3% | 13.2% | 10.9% | |||
| ROA, % | ? | 5.37% | 6.63% | 5.57% | 6.40% | 5.79% | 5.16% | |||
| P/E | ? | 29.4 | 34.2 | 47.5 | 22.8 | 25.5 | 24.7 | |||
| P/FCF | 21.7 | 32.8 | 34.9 | 37.5 | 33.1 | 18.2 | ||||
| P/S | ? | 2.82 | 4.27 | 5.25 | 2.78 | 2.93 | 2.51 | |||
| P/BV | ? | -12.4 | -25.9 | -15.0 | -13.4 | -33.4 | -84.4 | |||
| EV/EBITDA | ? | 15.8 | 18.9 | 24.9 | 13.5 | 14.4 | 12.9 | |||
| Debt/EBITDA | 3.04 | 2.51 | 3.13 | 2.76 | 2.70 | 2.57 | ||||
| R&D/CAPEX, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| CAPEX/Revenue, % | 5.36% | 5.70% | 6.46% | 8.17% | 7.71% | 5.80% | ||||
| Charles River Laboratories International shareholders | ||||||||||
